Inclusion Criteria:

          -  Participants must have an advanced solid tumor that has progressed on standard
             therapies known to provide clinical benefit or the participants are intolerant to such
             therapies.

          -  Participants have adequate bone marrow, renal, hepatic and coagulation function.

          -  For all dose expansion arms, participants must have measurable disease per Response
             Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

          -  Participants in combination therapy cohorts must have an advanced solid tumor where
             the use of nivolumab is standard therapy.

        Exclusion Criteria:

          -  Active or prior documented autoimmune disease in the last 2 years. Participants with
             childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or
             psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.

          -  Current or prior use of immunosuppressive medication within 14 days prior to the first
             dose (with certain exceptions).

          -  History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic
             leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis.

          -  Confirmed positive test results for human immunodeficiency virus (HIV), or
             participants with chronic or active hepatitis B or C. Participants who have a history
             of hepatitis B or C who have undetectable HBV DNA or HCV RNA after anti-viral therapy
             may be enrolled.

          -  Prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis
             (or any other unresolved or symptomatic adverse event in the last 3 months) while
             receiving immunotherapy.

          -  Male participants who are considering fathering a child or donating sperm during the
             study or for at least 3 or 5 months (for monotherapy and combination therapy
             participants, respectively) after the last dose of study drug.